Still awaiting official confirmation over HTEP (human tissue engineered products) transfer:
This article was originally published in Clinica
Executive Summary
Formal confirmation of the transfer of human tissue engineered products to the pharmaceuticals unit of the European Commission, and an associated change in regulatory orientation, did not happen at the Medical Devices Experts Group (MDEG) meeting in Luxembourg on April 12-13. It had been thought that a representative from the pharmaceuticals unit within Directorate F present would be present, but there is ongoing speculation that formal clearance to make the announcement was - and still is - awaited. The indications are that the Commission is to regulate human tissue engineered products, henceforth to be known as Advanced Therapies, alongside pharmaceuticals, thus dropping the concept of the separate "third pillar" of regulation.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.